Roivant Sciences Ltd. (NASDAQ:ROIV) Receives $33.59 Consensus Price Target from Analysts

Roivant Sciences Ltd. (NASDAQ:ROIV) has earned a consensus recommendation of “Moderate Buy” from the twelve ratings firms that are currently covering the company, MarketBeat reports. One analyst has rated the stock with a sell rating, one has assigned a hold rating and ten have issued a buy rating on the company. The average twelve-month price target among brokerages that have covered the stock in the last year is $33.5909.

Several equities research analysts have commented on the company. TD Cowen upped their price objective on Roivant Sciences from $38.00 to $41.00 and gave the stock a “buy” rating in a research report on Thursday, May 21st. HC Wainwright reissued a “buy” rating and set a $34.00 price target on shares of Roivant Sciences in a report on Thursday, May 21st. Piper Sandler restated an “overweight” rating on shares of Roivant Sciences in a research report on Thursday, May 21st. Guggenheim upped their price objective on shares of Roivant Sciences from $30.00 to $36.00 and gave the stock a “buy” rating in a research report on Tuesday, May 26th. Finally, Citigroup increased their target price on shares of Roivant Sciences from $35.00 to $42.00 and gave the stock a “buy” rating in a research note on Thursday, May 21st.

Roivant Sciences Stock Up 5.0%

Roivant Sciences stock opened at $34.52 on Friday. The firm has a market cap of $24.83 billion, a price-to-earnings ratio of -57.53 and a beta of 1.11. Roivant Sciences has a 52 week low of $10.90 and a 52 week high of $37.00. The business’s 50-day moving average price is $32.55 and its 200 day moving average price is $29.02.

Insider Buying and Selling

In other news, CEO Eric Venker sold 200,000 shares of the business’s stock in a transaction that occurred on Wednesday, June 24th. The stock was sold at an average price of $33.16, for a total value of $6,632,000.00. Following the completion of the sale, the chief executive officer directly owned 1,613,063 shares in the company, valued at $53,489,169.08. The trade was a 11.03% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Daniel Allen Gold sold 800,000 shares of the company’s stock in a transaction that occurred on Monday, June 29th. The stock was sold at an average price of $34.55, for a total value of $27,640,000.00. Following the transaction, the director directly owned 13,701,546 shares of the company’s stock, valued at approximately $473,388,414.30. The trade was a 5.52% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders sold 2,055,913 shares of company stock valued at $69,639,633. 10.80% of the stock is owned by company insiders.

Institutional Trading of Roivant Sciences

A number of institutional investors and hedge funds have recently modified their holdings of the stock. SBI Securities Co. Ltd. grew its stake in Roivant Sciences by 1,740.3% during the 4th quarter. SBI Securities Co. Ltd. now owns 1,233 shares of the company’s stock valued at $27,000 after acquiring an additional 1,166 shares in the last quarter. Allworth Financial LP grew its holdings in shares of Roivant Sciences by 48.1% during the 3rd quarter. Allworth Financial LP now owns 1,795 shares of the company’s stock worth $27,000 after purchasing an additional 583 shares during the period. Parallel Advisors LLC raised its stake in shares of Roivant Sciences by 33.7% in the 1st quarter. Parallel Advisors LLC now owns 2,065 shares of the company’s stock valued at $57,000 after acquiring an additional 520 shares during the period. Kestra Advisory Services LLC acquired a new position in Roivant Sciences during the fourth quarter worth $47,000. Finally, Bessemer Group Inc. lifted its stake in Roivant Sciences by 21.8% during the 1st quarter. Bessemer Group Inc. now owns 2,465 shares of the company’s stock worth $69,000 after acquiring an additional 441 shares in the last quarter. Hedge funds and other institutional investors own 64.76% of the company’s stock.

Roivant Sciences Company Profile

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women’s health.